{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:26:08Z","timestamp":1793597168603,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40257-026-01080-9","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:25:37Z","timestamp":1792232737000},"page":"1257-1269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From MAPK Reactivation to Response: Clinical Approaches Targeting BRAF\/MEK Resistance in Melanoma"],"prefix":"10.1007","volume":"27","author":[{"given":"Turkan Ozturk","family":"Topcu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7i\u011fdem","family":"Din\u00e7kal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-7030","authenticated-orcid":false,"given":"Zeynep","family":"Eroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"issue":"1","key":"1080_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40257-020-00572-6","volume":"22","author":"O Dulgar","year":"2021","unstructured":"Dulgar O, Kutuk T, Eroglu Z. Mechanisms of resistance to BRAF-targeted melanoma therapies. Am J Clin Dermatol. 2021;22(1):1\u201310. https:\/\/doi.org\/10.1007\/s40257-020-00572-6.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"1080_CR2","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1904059.","journal-title":"N Engl J Med"},{"issue":"7","key":"1080_CR3","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","volume":"20","author":"H Rizos","year":"2014","unstructured":"Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res. 2014;20(7):1965\u201377. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3122.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1080_CR4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","volume":"174","author":"F Rambow","year":"2018","unstructured":"Rambow F, Rogiers A, Marin-Bejar O, et al. Toward minimal residual disease-directed therapy in melanoma. Cell. 2018;174(4):843\u201355.","journal-title":"Cell"},{"issue":"1","key":"1080_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35\u201344.","journal-title":"Cell"},{"issue":"7","key":"1080_CR6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s43018-021-00221-9","volume":"2","author":"L Haas","year":"2021","unstructured":"Haas L, Elewaut A, Gerard CL, et al. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nat Cancer. 2021;2(7):693\u2013708.","journal-title":"Nat Cancer"},{"issue":"2","key":"1080_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins MB, Lee SJ, Chmielowski B, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq Trial. J Clin Oncol. 2023;41(2):186\u201397.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1080_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(22)00687-8","volume":"24","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Stroyakovskiy D, Gogas H, et al. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis. Lancet Oncol. 2023;24(1):33\u201344.","journal-title":"Lancet Oncol"},{"issue":"10240","key":"1080_CR9","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis. Lancet. 2020;395(10240):1835\u201344.","journal-title":"Lancet"},{"issue":"6","key":"1080_CR10","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","volume":"162","author":"W Hugo","year":"2015","unstructured":"Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell. 2015;162(6):1271\u201385. https:\/\/doi.org\/10.1016\/j.cell.2015.07.061.","journal-title":"Cell"},{"issue":"9","key":"1080_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-018-0081-3","volume":"7","author":"M Irvine","year":"2018","unstructured":"Irvine M, Stewart A, Pedersen B, Boyd S, Kefford R, Rizos H. Oncogenic PI3K\/AKT promotes the step-wise evolution of combination BRAF\/MEK inhibitor resistance in melanoma. Oncogenesis. 2018;7(9):72. https:\/\/doi.org\/10.1038\/s41389-018-0081-3.","journal-title":"Oncogenesis"},{"key":"1080_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1727","volume":"3","author":"H Shi","year":"2012","unstructured":"Shi H, Moriceau G, Kong X, Lee M-K, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012;3:724. https:\/\/doi.org\/10.1038\/ncomms1727.","journal-title":"Nat Commun"},{"issue":"7377","key":"1080_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387\u201390. https:\/\/doi.org\/10.1038\/nature10662.","journal-title":"Nature"},{"issue":"6","key":"1080_CR14","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.celrep.2018.10.049","volume":"25","author":"MJ Vido","year":"2018","unstructured":"Vido MJ, Le K, Hartsough EJ, Aplin AE. BRAF splice variant resistance to RAF inhibitor requires enhanced MEK association. Cell Rep. 2018;25(6):1501\u201310. https:\/\/doi.org\/10.1016\/j.celrep.2018.10.049.","journal-title":"Cell Rep"},{"issue":"17","key":"1080_CR15","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1158\/0008-5472.CAN-14-1232-T","volume":"74","author":"IR Watson","year":"2014","unstructured":"Watson IR, Li L, Cabeceiras PK, et al. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res. 2014;74(17):4845\u201352. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1232-T.","journal-title":"Cancer Res"},{"issue":"1","key":"1080_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ccell.2019.05.015","volume":"36","author":"DA Lionarons","year":"2019","unstructured":"Lionarons DA, Hancock DC, Rana S, et al. RAC1P29S induces a mesenchymal phenotypic switch via serum response factor to promote melanoma development and therapy resistance. Cancer Cell. 2019;36(1):68\u201383. https:\/\/doi.org\/10.1016\/j.ccell.2019.05.015.","journal-title":"Cancer Cell"},{"issue":"7326","key":"1080_CR17","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/nature09627","volume":"468","author":"CM Johannessen","year":"2010","unstructured":"Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968\u201372. https:\/\/doi.org\/10.1038\/nature09627.","journal-title":"Nature"},{"issue":"1","key":"1080_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12943-025-02323-9","volume":"24","author":"S Liu","year":"2025","unstructured":"Liu S, Dong Z, Cui J, et al. Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment. Mol Cancer. 2025;24(1):23. https:\/\/doi.org\/10.1186\/s12943-025-02323-9.","journal-title":"Mol Cancer"},{"key":"1080_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s43556-026-00425-4","volume":"7","author":"Y Shang","year":"2026","unstructured":"Shang Y, Zhang W, Yao Q, et al. BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations. Mol Biomed. 2026;7:27. https:\/\/doi.org\/10.1186\/s43556-026-00425-4.","journal-title":"Mol Biomed"},{"issue":"2","key":"1080_CR20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/cas.70418","volume":"117","author":"B Shah","year":"2026","unstructured":"Shah B, Raghavan S, Bhattacharya R, et al. MAPK inhibitor-tolerant persister cells in melanoma: mechanisms and therapeutic vulnerabilities. Cancer Sci. 2026;117(2):298\u2013312. https:\/\/doi.org\/10.1111\/cas.70418.","journal-title":"Cancer Sci"},{"issue":"7","key":"1080_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41568-019-0154-4","volume":"19","author":"I Arozarena","year":"2019","unstructured":"Arozarena I, Wellbrock C. Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer. 2019;19(7):377\u201391. https:\/\/doi.org\/10.1038\/s41568-019-0154-4.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1080_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jid.2021.10.007","volume":"142","author":"RW Jenkins","year":"2021","unstructured":"Jenkins RW, Sullivan RJ. Vemurafenib drives epithelial-to-mesenchymal transition gene expression in BRAF inhibitor-resistant BRAFV600E\/NRASQ61K melanoma. J Investig Dermatol. 2021;142(2):371\u201382. https:\/\/doi.org\/10.1016\/j.jid.2021.10.007.","journal-title":"J Investig Dermatol"},{"issue":"5","key":"1080_CR23","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1158\/0008-5472.CAN-24-0690","volume":"85","author":"JC Rubinstein","year":"2025","unstructured":"Rubinstein JC, Domanskyi S, Sheridan TB, et al. Spatiotemporal profiling defines persistence and resistance dynamics during targeted treatment of melanoma. Cancer Res. 2025;85(5):987\u20131002. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-0690.","journal-title":"Cancer Res"},{"issue":"5","key":"1080_CR24","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","volume":"33","author":"J Tsoi","year":"2018","unstructured":"Tsoi J, Robert L, Paraiso K, et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell. 2018;33(5):890\u2013904. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.017.","journal-title":"Cancer Cell"},{"key":"1080_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6712","volume":"5","author":"J Muller","year":"2014","unstructured":"Muller J, Krijgsman O, Tsoi J, et al. Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014;5:5712. https:\/\/doi.org\/10.1038\/ncomms6712.","journal-title":"Nat Commun"},{"issue":"6","key":"1080_CR26","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-21-3382","volume":"28","author":"JM Mehnert","year":"2022","unstructured":"Mehnert JM, Mitchell TC, Huang AC, Aleman TS, Kim BJ, Schuchter LM, et al. BAMM (BRAF autophagy and MEK inhibition in melanoma): a phase I\/II trial of dabrafenib, trametinib, and hydroxychloroquine in advanced BRAFV600-mutant melanoma. Clin Cancer Res. 2022;28(6):1098\u2013106. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3382.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1080_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/cancers8030030","volume":"8","author":"RK Amaravadi","year":"2016","unstructured":"Amaravadi RK, Winkler JD, Keith B, et al. Melanoma and the unfolded protein response. Cancers (Basel). 2016;8(3):30. https:\/\/doi.org\/10.3390\/cancers8030030.","journal-title":"Cancers (Basel)"},{"issue":"7436","key":"1080_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature11814","volume":"494","author":"M Das Thakur","year":"2013","unstructured":"Das Thakur M, Salangsang F, Landman AS, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013;494(7436):251\u20135. https:\/\/doi.org\/10.1038\/nature11814.","journal-title":"Nature"},{"issue":"10","key":"1080_CR29","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/s41591-020-1060-8","volume":"26","author":"AP Algazi","year":"2020","unstructured":"Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, et al. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020;26(10):1564\u20138. https:\/\/doi.org\/10.1038\/s41591-020-1060-8.","journal-title":"Nat Med"},{"issue":"1","key":"1080_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26572-6","volume":"12","author":"M Gonzalez-Cao","year":"2021","unstructured":"Gonzalez-Cao M, Mayo de las Casas C, Oramas J, Berciano-Guerrero MA, de la Cruz L, Cerezuela P, et al. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nat Commun. 2021;12(1):7008. https:\/\/doi.org\/10.1038\/s41467-021-26572-6.","journal-title":"Nat Commun"},{"issue":"1","key":"1080_CR31","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20166796","volume":"13","author":"M Fallahi-Sichani","year":"2017","unstructured":"Fallahi-Sichani M, Becker V, Izar B, Baker GJ, Lin JR, Boswell SA, et al. Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. Mol Syst Biol. 2017;13(1):MSB166796. https:\/\/doi.org\/10.15252\/msb.20166796.","journal-title":"Mol Syst Biol"},{"issue":"7408","key":"1080_CR32","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500\u20134. https:\/\/doi.org\/10.1038\/nature11183.","journal-title":"Nature"},{"issue":"8","key":"1080_CR33","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm.4123","volume":"22","author":"H Jiang","year":"2016","unstructured":"Jiang H, Hegde S, Knolhoff BL, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22(8):851\u201360. https:\/\/doi.org\/10.1038\/nm.4123.","journal-title":"Nat Med"},{"issue":"11","key":"1080_CR34","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/0008-5472.CAN-16-2675","volume":"77","author":"M Vouri","year":"2017","unstructured":"Vouri M, Hafizi S. TAM receptor tyrosine kinases in cancer drug resistance. Cancer Res. 2017;77(11):2775\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2675.","journal-title":"Cancer Res"},{"key":"1080_CR35","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1038\/s41598-022-09078-z","volume":"12","author":"DJ Konieczkowski","year":"2022","unstructured":"Konieczkowski DJ, Johannessen CM, Garraway LA. AXL inhibition improves BRAF-targeted treatment in melanoma. Sci Rep. 2022;12:5078. https:\/\/doi.org\/10.1038\/s41598-022-09078-z.","journal-title":"Sci Rep"},{"issue":"10","key":"1080_CR36","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/2326-6066.CIR-19-0008","volume":"7","author":"A Holtzhausen","year":"2019","unstructured":"Holtzhausen A, Harris W, Ubil E, et al. TAM family receptor kinase inhibition reverses MDSC-mediated suppression and augments anti-PD-1 therapy in melanoma. Cancer Immunol Res. 2019;7(10):1672\u201386. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0008.","journal-title":"Cancer Immunol Res"},{"issue":"16","key":"1080_CR37","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-25-0884","volume":"31","author":"D Davar","year":"2025","unstructured":"Davar D, Eroglu Z, Llacer Perez C, et al. Combined targeting of PD-1 and TIM-3 in patients with locally advanced or metastatic melanoma: AMBER cohorts 1c, 1e, and 2A. Clin Cancer Res. 2025;31(16):3433\u201342. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0884.","journal-title":"Clin Cancer Res"},{"key":"1080_CR38","doi-asserted-by":"publisher","first-page":"44475","DOI":"10.1200\/JCO.21.02961","volume":"15","author":"PA Ascierto","year":"2024","unstructured":"Ascierto PA, Mandala M, Gogas H, et al. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): 4-year survival outcomes. Nat Commun. 2024;15:44475. https:\/\/doi.org\/10.1200\/JCO.21.02961.","journal-title":"Nat Commun"},{"issue":"2","key":"1080_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001806","volume":"8","author":"PF Ferrucci","year":"2020","unstructured":"Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, et al. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer. 2020;8(2):e001806. https:\/\/doi.org\/10.1136\/jitc-2020-001806.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"1080_CR40","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1200\/JCO.21.01601","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer R, Long GV, Robert C, et al. Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma. J Clin Oncol. 2022;40(11):1194\u2013206. https:\/\/doi.org\/10.1200\/JCO.21.01601.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1080_CR41","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","volume":"22","author":"HA Tawbi","year":"2021","unstructured":"Tawbi HA, Forsyth PA, Hodi FS, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021;22(12):1692\u2013704. https:\/\/doi.org\/10.1016\/S1470-2045(21)00545-3.","journal-title":"Lancet Oncol"},{"issue":"Suppl. 17","key":"1080_CR42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA9507","volume":"43","author":"Z Eroglu","year":"2025","unstructured":"Eroglu Z, Moon J, Najjar Y, et al. A randomized phase 2 trial of encorafenib\u00a0+\u00a0binimetinib\u00a0+\u00a0nivolumab vs ipilimumab\u00a0+\u00a0nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013). J Clin Oncol. 2025;43(Suppl. 17):LBA9507. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA9507.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1080_CR43","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1158\/2159-8290.CD-17-1355","volume":"8","author":"I Smalley","year":"2018","unstructured":"Smalley I, Smalley KSM. ERK inhibition: a new front in the war against MAPK pathway-driven cancers? Cancer Discov. 2018;8(2):140\u20132. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1355.","journal-title":"Cancer Discov"},{"issue":"2","key":"1080_CR44","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","volume":"8","author":"RJ Sullivan","year":"2018","unstructured":"Sullivan RJ, Infante JR, Janku F, et al. First-in-class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study. Cancer Discov. 2018;8(2):184\u201395. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1119.","journal-title":"Cancer Discov"},{"issue":"2","key":"1080_CR45","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1158\/1535-7163.MCT-19-0183","volume":"19","author":"SV Bhagwat","year":"2020","unstructured":"Bhagwat SV, McMillen WT, Cai S, et al. ERK inhibitor LY3214996 targets ERK pathway-driven cancers: a therapeutic approach toward precision medicine. Mol Cancer Ther. 2020;19(2):325\u201336. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0183.","journal-title":"Mol Cancer Ther"},{"issue":"7574","key":"1080_CR46","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nature14982","volume":"526","author":"C Zhang","year":"2015","unstructured":"Zhang C, Spevak W, Zhang Y, et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature. 2015;526(7574):583\u20136. https:\/\/doi.org\/10.1038\/nature14982.","journal-title":"Nature"},{"issue":"3","key":"1080_CR47","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/pcmr.12218","volume":"27","author":"KJ Basile","year":"2014","unstructured":"Basile KJ, Le K, Hartsough EJ, Aplin AE. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res. 2014;27(3):479\u201384. https:\/\/doi.org\/10.1111\/pcmr.12218.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"9","key":"1080_CR48","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1158\/2159-8290.CD-24-0024","volume":"14","author":"R Yaeger","year":"2024","unstructured":"Yaeger R, Weiss J, Pelster MS, et al. A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers. Cancer Discov. 2024;14(9):1599\u2013611. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0024.","journal-title":"Cancer Discov"},{"issue":"16_Suppl.","key":"1080_CR49","doi-asserted-by":"publisher","first-page":"9512","DOI":"10.1200\/JCO.2026.44.16_suppl.9512","volume":"44","author":"MF Chen","year":"2026","unstructured":"Chen MF, Butler MO, Rodon Ahnert J, Hall ET, Eroglu Z, Rose AAN, et al. Phase 1b study of a brain-penetrant MEK inhibitor, PF-07799544, plus next-generation BRAF dimer inhibitor, PF-07799933, in advanced BRAF-mutant melanoma. J Clin Oncol. 2026;44(16_Suppl.):9512. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.9512.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1080_CR50","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/pcmr.12303","volume":"27","author":"VW Rebecca","year":"2014","unstructured":"Rebecca VW, Alicea GM, Paraiso KH, et al. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res. 2014;27(6):1154\u20138. https:\/\/doi.org\/10.1111\/pcmr.12303.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1080_CR51","doi-asserted-by":"publisher","unstructured":"Ascierto PA, Bechter O, Wolter P, et al. A phase Ib\/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK4\/6 (ribociclib) inhibitor in patients with BRAF V600-mutant solid tumors and melanoma. J Clin Oncol. 2017;35(15_Suppl.):9518. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.9518.","DOI":"10.1200\/JCO.2017.35.15_suppl.9518"},{"key":"1080_CR52","doi-asserted-by":"publisher","unstructured":"Chan J, Dixon Douglas JR, Xie J, Khoo C, Soon J, Weppler A, et al. A phase Ib study to evaluate the safety, tolerability and efficacy of the combination of encorafenib, binimetinib and palbociclib in patients with BRAF-mutant metastatic melanoma (CELEBRATE). Ann Oncol. 2025;36(2_Suppl.):S912. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2273.","DOI":"10.1016\/j.annonc.2025.08.2273"},{"issue":"1","key":"1080_CR53","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1038\/s41467-020-19077-1","volume":"11","author":"R Tripathi","year":"2020","unstructured":"Tripathi R, Liu Z, Jain A, Lyon A, Meeks C, Richards D, et al. Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1\/2-mediated reactivation of MEK\/ERK\/MYC signaling. Nat Commun. 2020;11(1):5463. https:\/\/doi.org\/10.1038\/s41467-020-19077-1.","journal-title":"Nat Commun"},{"key":"1080_CR54","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ebiom.2019.09.023","volume":"48","author":"I Smalley","year":"2019","unstructured":"Smalley I, Kim E, Li J, Spence P, Wyatt CJ, Eroglu Z, et al. Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine. 2019;48:178\u201390. https:\/\/doi.org\/10.1016\/j.ebiom.2019.09.023.","journal-title":"EBioMedicine"},{"issue":"5","key":"1080_CR55","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S1470-2045(25)00139-1","volume":"26","author":"MM Syeda","year":"2025","unstructured":"Syeda MM, Long GV, Garrett J, et al. Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial. Lancet Oncol. 2025;26(5):641\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(25)00139-1.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1080_CR56","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(20)30726-9","volume":"22","author":"MM Syeda","year":"2021","unstructured":"Syeda MM, Wiggins JM, Corless BC, et al. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncol. 2021;22(3):370\u201380. https:\/\/doi.org\/10.1016\/S1470-2045(20)30726-9.","journal-title":"Lancet Oncol"},{"key":"1080_CR57","unstructured":"US FDA. FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. February 16, 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma. Accessed 6 Oct 2026."},{"issue":"33","key":"1080_CR58","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1200\/JCO-25-00765","volume":"43","author":"T Medina","year":"2025","unstructured":"Medina T, Chesney JA, Kluger HM, et al. Long-term effi cacy and safety of lifi leucel tumor-infi ltrating lymphocyte celltherapy in patients with advanced melanoma: a 5-year analysis of the C-144-01 study. J Clin Oncol.2025;43(33):3565\u20133572. https:\/\/doi.org\/10.1200\/JCO-25-00765.","journal-title":"J Immunother Cancer"},{"key":"1080_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153754","volume":"15","author":"JN Priantti","year":"2023","unstructured":"Priantti JN, Vilbert M, Madeira T, et al. Efficacy and safety of rechallenge with BRAF\/MEK inhibitors in advanced melanoma patients: a systematic review and meta-analysis. Cancers (Basel). 2023;15:3754. https:\/\/doi.org\/10.3390\/cancers15153754.","journal-title":"Cancers (Basel)"},{"key":"1080_CR60","unstructured":"US FDA. FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma. August 6, 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma. Accessed 6 Oct 2026."},{"issue":"1","key":"1080_CR61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1373\/clinchem.2014.230235","volume":"61","author":"MF Sanmamed","year":"2015","unstructured":"Sanmamed MF, Fern\u00e1ndez-Land\u00e1zuri S, Rodr\u00edguez C, et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem. 2015;61(1):297\u2013304. https:\/\/doi.org\/10.1373\/clinchem.2014.230235.","journal-title":"Clin Chem"},{"key":"1080_CR62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/PO.19.00174","volume":"4","author":"J Braune","year":"2020","unstructured":"Braune J, Keller L, Schiller F, Graf E, Rafei-Shamsabadi D, Wehrle J, et al. Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma. JCO Precis Oncol. 2020;4:20\u201331. https:\/\/doi.org\/10.1200\/PO.19.00174.","journal-title":"JCO Precis Oncol"},{"issue":"15","key":"1080_CR63","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1200\/JCO.22.02072","volume":"41","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Bono P, Bhatia S, et al. Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1\/programmed death ligand 1 therapy: results from the phase I\/IIa RELATIVITY-020 trial. J Clin Oncol. 2023;41(15):2724\u201335. https:\/\/doi.org\/10.1200\/JCO.22.02072.","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01080-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01080-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01080-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T04:26:07Z","timestamp":1793593567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01080-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1080"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01080-9","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zeynep Eroglu has received advisory role fees from Replimune, Pfizer, Regeneron, Natera, and Sun Pharma; research funding from Boehringer Ingelheim (to institution) and Pfizer (to institution). Turkan Ozturk Topcu and \u00c7i\u011fdem Din\u00e7kal have no conflicts that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of Interest\/Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors were involved in the drafting, researching, writing, and revising of the manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}